XML 38 R29.htm IDEA: XBRL DOCUMENT
v3.21.1

Shareholders' Equity (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2021
Equity [Abstract] |
Schedule of Components of Shareholder's Equity | The following tables show changes in components of shareholders’ equity for the three months ended March 31, 2021 (unaudited and in thousands).
|  | Common Stock |  |  | Accumulated Other Comprehensive |  |  | Accumulated |  |  | Total Shareholders’ |
|  | Shares |  |  | Amount |  |  | Loss |  |  | Deficit |  |  | Equity |
BALANCE AT JANUARY 1, 2021 |  |  | 69,117 |  |  | $ | 157,160 |  |  | $ | - |  |  | $ | (123,677) |  |  | $ | 33,483 |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (3,919) |  |  |  | (3,919) |
Stock-based compensation |  |  | - |  |  |  | 1,290 |  |  |  | - |  |  |  | - |  |  |  | 1,290 |
Sale of common shares, including at-the-market transactions |  |  | 18,427 |  |  |  | 71,746 |  |  |  | - |  |  |  | - |  |  |  | 71,746 |
Financing costs paid to issue common shares, including at-the-market transactions |  |  | - |  |  |  | (2,878) |  |  |  | - |  |  |  | - |  |  |  | (2,878) |
Exercise of stock options |  |  | 140 |  |  |  | 348 |  |  |  | - |  |  |  | - |  |  |  | 348 |
Exercise of warrants |  |  | 248 |  |  |  | 802 |  |  |  | - |  |  |  | - |  |  |  | 802 |
Issuance of common stock to Razor Genomics |  |  | 982 |  |  |  | 5,756 |  |  |  | - |  |  |  | - |  |  |  | 5,756 |
BALANCE AT MARCH 31, 2021 |  |  | 88,914 |  |  | $ | 234,224 |  |  | $ | - |  |  | $ | (127,596) |  |  | $ | 106,628 |
The following table shows changes in components of shareholders’ equity for the three months ended March 31, 2020 (unaudited and in thousands).
|  | Common Stock |  |  | Accumulated Other Comprehensive |  |  | Accumulated |  |  | Total Shareholders’ |
|  | Shares |  |  | Amount |  |  | Loss |  |  | Deficit |  |  | Equity |
BALANCE AT JANUARY 1, 2020 |  |  | 57,032 |  |  | $ | 124,583 |  |  | $ | - |  |  | $ | (93,745) |  |  | $ | 30,838 |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (7,732) |  |  |  | (7,732) |
Stock-based compensation |  |  | - |  |  |  | 937 |  |  |  | - |  |  |  | - |  |  |  | 937 |
Sale of common shares |  |  | 3,523 |  |  |  | 7,597 |  |  |  | - |  |  |  | - |  |  |  | 7,597 |
Financing costs paid to issue common shares |  |  | - |  |  |  | (1) |  |  |  | - |  |  |  | - |  |  |  | (1) |
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes |  |  | 13 |  |  |  | (14) |  |  |  | - |  |  |  | - |  |  |  | (14) |
Issuance of common stock for Insight Genetics acquisition |  |  | 1,916 |  |  |  | 5,000 |  |  |  | - |  |  |  | - |  |  |  | 5,000 |
BALANCE AT MARCH 31, 2020 |  |  | 62,484 |  |  | $ | 138,102 |  |  | $ | - |  |  | $ | (101,477) |  |  | $ | 36,625 |

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration